Late stage market of influenza and severe cold, anti herpesvirus drugs are in danger

Among the antiviral drugs, broad-spectrum antiviral drugs developed rapidly at the end of the 20th century The rapid growth of the number of antiviral drugs and the amount of antiviral drugs has objectively promoted the overall level of antiviral drugs market In the newly issued catalogue of national basic medical insurance, work injury insurance and maternity insurance drugs in 2017, the broad-spectrum antiviral nucleoside and nucleotide drugs include acyclovir, famciclovir, ganciclovir, valaciclovir, ribavirin, and other antiviral drugs include sodium phosphonate, which basically covers the common antiviral and antiherpesvirus drugs In recent years, influenza and severe cold have ravaged the land of China In the later period of influenza and severe cold, all kinds of virus infections are likely to emerge, which deserves people's attention   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> the market growth of antiviral drugs in China is significant Virus is the main culprit of human multiple infectious diseases The disease caused by virus is very dangerous and has a wide range of influence In the current major epidemic diseases, the diseases caused by viruses account for more than half So far, more than 3600 kinds of viruses have been found in the world, and new viruses are still being found, which is one of the biggest puzzles faced by human health In recent years, under the wanton spread of the virus, the epidemic situation is one after another, which objectively promotes the rapid development of the research and development of antiviral drugs In the research and development pipeline of antiviral drugs, drug preparations that directly act on viruses have developed rapidly and play an important role in anti infective drugs However, drugs with high selectivity, acting on viral cell metabolism and no obvious damage to the host are the focus of new drug research and development at home and abroad According to the data of minenet, in 2016, the market of antiviral drugs in public hospitals in key cities in China was 2.424 billion yuan, an increase of 11.88% over the previous year, which is the category with higher growth rate among anti infective drugs According to the statistics in the first three quarters of 2017, the market of antiviral drugs in public hospitals in key cities in China is predicted to be 2.658 billion yuan in 2017, an increase of 9.68% over the previous year Under the hospital's anti-bacterial orders and the adverse reactions of fluoroquinolones, antibacterial drugs have entered the normal development However, antiviral drugs show a trend of increasing year by year, and the development trend is gradually in line with the global pharmaceutical market, especially after the listing of anti HCV drugs, the domestic antiviral drug market will increase significantly in 2018 Figure 1: antiviral drug market of public hospitals in key cities in China in 2016 (unit: 100 million yuan) none = "shifumousedownstyle ('shifu bus_ ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> the domestic market for broad-spectrum antiviral drugs and anti herpes drugs is not ideal In the past two years, the global R & D pipeline of antiviral drugs has continued to move forward, and many new drugs have appeared in the domestic antiviral market, but the broad-spectrum antiviral drugs and anti herpes drugs are far inferior to anti HCV Anti HIV and anti HBV drugs are developing rapidly, and there is still a certain gap between domestic hospital antiviral drugs and global antiviral drugs market According to data from minenet, in 2017, the market forecast of broad-spectrum antiviral drugs and antiherpetic drugs in public hospitals in key cities in China is nearly 300 million yuan, with a year-on-year growth rate of only 2.91% In clinical application of broad-spectrum antiviral drugs, the main varieties are ganciclovir, valaciclovir, acyclovir, famciclovir, valgenclovir, ribavirin, sodium phosphonate, adenosine arabinoside, etc Figure 2: in 2017, the market of broad-spectrum antiviral drugs and antiherpes drugs in public hospitals of key cities in China (unit: 100 million yuan) according to the data of minenet, from 2007 to 2010, the average growth rate of the amount of broad-spectrum antiviral drugs and antiherpes drugs in public hospitals of key cities in China was about 20%, showing a high growth rate In the past five years, the growth of broad-spectrum antiviral drugs and antiherpetic drugs has been slow by half under the strong increase of drug bidding, procurement and proprietary Chinese medicine From 2013 to 2017, the average growth rate of the amount of broad-spectrum antiviral drugs and antiherpetic drugs used in public hospitals in key cities in China was 4.71%; among them, 35.33% were treated with cytomegalovirus (CMV), including ganciclovir, sodium phosphonate and valgenclovir; 59.34% were antiherpesvirus drugs, and 5.33% were other broad-spectrum antiviral drugs Fig 3: market overview of broad-spectrum antiviral drugs and antiherpetic drugs in public hospitals of key cities in China from 2013 to 2017 None = "shifumousedownstyle ('shifu bus [002 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> viral herpes should not be underestimated Viral herpes is a viral skin disease caused by viral herpes virus, which is divided into herpes simplex, herpes zoster and facial herpes Herpes simplex invades the junction of skin and mucous membrane, which is characterized by localized clustered vesicles; herpes zoster is characterized by dense vesicles distributed along the peripheral nerves on one side Herpes zoster, commonly known as "lumbosaurus" and "spider sore", is a disease that invades the waist of the elderly The virus can lurk in the dorsal root ganglia of the spinal cord for a long time, which is prone to occur in the winter and spring when the immunity drops; facial Herpes zoster mainly affects the skin around the face and lips of adults and children It is also a disease in the later stage of influenza and severe cold   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the domestic live attenuated shingles vaccine has been approved for marketing abroad The elderly and those susceptible to shingles are vaccinated against shingles The sales revenue of Zostavax, the herpes vaccine of MSD in 2016, was US $685 million So far, there is no herpes vaccine on the market in China, but according to CFDA data, the live attenuated herpes zoster vaccine of Shanghai Institute of biological products (2017l04524) and Changchun Qijian biological products (2017l04536) has obtained clinical approval in August 2017, and the freeze-dried live attenuated herpes zoster vaccine of Beijing Wantai biological pharmaceutical Co., Ltd has been in the development and review report After the herpes vaccine goes on the market, it will be another best-selling product in the domestic vaccine market   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> adenosine arabinose accounts for 40% of the market of anti herpesvirus drugs According to the data of minenet, in 2017, the market of anti herpesvirus chemicals in public hospitals in key cities in China is predicted to be 168 million yuan, with a growth rate of only 2.5% over the previous year There are 476 registration approvals for 6 varieties in total In 2017, the proportion of 6 antiherpetic drugs in the small market of public hospitals in key cities in China is as follows: adenosine arabinose 41.41%, valaciclovir 29.07%, acyclovir 12.14%, famciclovir 9.85%, penciclovir 6.38%, brovudine 1.15% Figure 4: antiherpetic drug market of public hospitals in key cities of China in 2017 (unit: 10000 yuan) Figure 5: six antiherpetic drug markets in public hospitals in key cities of China in 2017 (unit: 10000 yuan) none = "shifumousedownstyle ('shifu_bus_002 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB ", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> in the last two months of 2017, the U.S FDA approved more than 10 new molecular entity drugs, accounting for 24% of the whole year On November 8, 2017, the U.S FDA approved letermovir, an antiviral drug of mesardon, which includes tablets and intravenous preparations, trade name "prevymis", applicable to adult recipients (R +) of cytomegalovirus (CMV) - positive allogeneic hematopoietic stem cell transplantation (allo HSCT), and can be used to prevent cytomegalovirus infection It is worth mentioning that locomovir is the only drug approved by the US market for anti cytomegalovirus use in the past 15 years According to the data of mienei.com, it is estimated that the market of anti cytomegalovirus drugs for public hospitals in key cities in China will be 100 million yuan in 2017, with a year-on-year growth rate of 5.11% In China, ganciclovir, valgenclovir and foscarnet sodium are the common anti cytomegalovirus drugs These three drugs can alleviate the infection of CMV, inhibit the DNA polymerase of CMV competitively and stop the growth of DNA chain of CMV It can prevent pneumonia in the treatment of cytomegalovirus At present, there are many brands in the market The original drugs are "cymevene" and "valcyte" of Roche.